Extracellular Vesicles in Cancer: Biomarkers, Mechanisms, and Emerging Diagnostic Technologies.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 42503304.
- Also identified by DOI 10.1002/adhm.71462.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Extracellular vesicles (EVs) are nanoscale, membrane-bound particles that transport diverse biomolecules-including proteins, nucleic acids, lipids, and metabolites-between cells, thereby orchestrating key processes in cancer progression. Tumor-derived EVs modulate angiogenesis, epithelial-to-mesenchymal transition, extracellular matrix remodeling, fibroblast activation, and immune evasion, shaping the tumor microenvironment, and driving metastasis as well as therapy resistance. With their stability in biofluids and cargo reflective of cellular origin, EVs have emerged as powerful non-invasive biomarkers for early detection, disease monitoring, and prognosis across multiple cancer types. Recent advances in enrichment, characterization, and molecular profiling technologies-ranging from ultracentrifugation and microfluidics to proteomics, RNA sequencing, and surface-enhanced Raman spectroscopy, have greatly expanded the diagnostic potential of EVs. Integration with machine learning further enhances sensitivity, specificity, and tumor classification, while multiomic and multiplex platforms enable high-throughput and clinically relevant applications. This review highlights the multifaceted roles of EVs in cancer biology, catalogs emerging biomarkers, and compares state-of-the-art detection technologies, offering a comprehensive reference for advancing EV-based diagnostics and precision oncology.